The explosion of interest in weight management drugs will continue in 2024 and is likely to remain a top issue for health plan sponsors as they deal with questions surrounding these popular, but sometimes controversial, drugs.
A recent webinar hosted by BenefitsPRO.com discussed the new weight management drugs, known as GLP-1s. The drugs reduce blood sugar and assist in weight loss and include high-profile drugs such as Ozempic and Wegovy. Two Noom experts, Dr. Linda Anegawa, chief of medicine for Noom at Work, and Jordan Galante, director of the company's national accounts, discussed the drugs and the changes they are bringing to the world of benefits.
Top predictions for 2024
The pair focused on seven key predictions for the upcoming year when it comes to GLP-1 drugs and their impact on employee benefits. The first prediction was that consumer demand will continue to fuel the rapid growth of new formulations of the drugs.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
